BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 155 filers reported holding BLUEBIRD BIO INC in Q2 2022. The put-call ratio across all filers is 1.50 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $2,735 | -54.0% | 860 | 0.0% | 0.00% | – |
Q4 2022 | $5,951 | +19.0% | 860 | 0.0% | 0.00% | – |
Q3 2022 | $5,000 | +25.0% | 860 | 0.0% | 0.00% | – |
Q2 2022 | $4,000 | 0.0% | 860 | 0.0% | 0.00% | – |
Q1 2022 | $4,000 | -55.6% | 860 | 0.0% | 0.00% | – |
Q4 2021 | $9,000 | -43.8% | 860 | 0.0% | 0.00% | – |
Q3 2021 | $16,000 | -42.9% | 860 | 0.0% | 0.00% | – |
Q2 2021 | $28,000 | 0.0% | 860 | -5.8% | 0.00% | – |
Q1 2021 | $28,000 | -97.2% | 913 | -96.1% | 0.00% | -100.0% |
Q4 2020 | $1,009,000 | -97.4% | 23,325 | -96.7% | 0.00% | -96.2% |
Q3 2020 | $38,146,000 | -10.2% | 707,068 | +1.6% | 0.03% | -18.8% |
Q2 2020 | $42,492,000 | +32.9% | 696,127 | +0.1% | 0.03% | -8.6% |
Q1 2020 | $31,970,000 | -47.6% | 695,608 | 0.0% | 0.04% | -40.7% |
Q4 2019 | $61,039,000 | -80.8% | 695,608 | -79.9% | 0.06% | -83.7% |
Q3 2019 | $317,313,000 | -40.9% | 3,455,816 | -18.2% | 0.36% | -36.7% |
Q2 2019 | $537,233,000 | -23.8% | 4,223,534 | -5.7% | 0.57% | -26.1% |
Q1 2019 | $704,697,000 | +56.8% | 4,479,101 | -1.1% | 0.77% | +32.0% |
Q4 2018 | $449,289,000 | -33.7% | 4,529,123 | -2.5% | 0.58% | -20.2% |
Q3 2018 | $677,956,000 | -10.8% | 4,643,528 | -4.1% | 0.73% | -10.7% |
Q2 2018 | $760,171,000 | -11.7% | 4,843,399 | -3.9% | 0.82% | -18.8% |
Q1 2018 | $860,932,000 | -6.8% | 5,042,067 | -2.8% | 1.01% | -12.1% |
Q4 2017 | $924,061,000 | +26.5% | 5,188,435 | -2.5% | 1.15% | +24.2% |
Q3 2017 | $730,730,000 | +28.8% | 5,320,202 | -1.5% | 0.92% | +21.2% |
Q2 2017 | $567,339,000 | +19.9% | 5,400,658 | +3.8% | 0.76% | +10.9% |
Q1 2017 | $473,102,000 | +48.5% | 5,204,633 | +0.8% | 0.69% | +31.3% |
Q4 2016 | $318,647,000 | -6.0% | 5,164,467 | +3.3% | 0.52% | -1.1% |
Q3 2016 | $338,821,000 | +54.9% | 4,998,833 | -1.1% | 0.53% | +35.9% |
Q2 2016 | $218,795,000 | +3.4% | 5,054,175 | +1.5% | 0.39% | +4.8% |
Q1 2016 | $211,549,000 | -32.5% | 4,977,637 | +1.9% | 0.37% | -31.7% |
Q4 2015 | $313,607,000 | -23.2% | 4,883,321 | +2.1% | 0.54% | -31.9% |
Q3 2015 | $408,534,000 | -34.4% | 4,783,704 | +29.4% | 0.80% | -28.5% |
Q2 2015 | $622,533,000 | +301.5% | 3,697,412 | +188.0% | 1.12% | +281.9% |
Q1 2015 | $155,064,000 | – | 1,283,962 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |